Merck’s Recarbrio Shows Success in Late-Stage Trial for HABP/VABP Patients

Merck’s Recarbrio Shows Success in Late-Stage Trial for HABP/VABP Patients

Source: 
BioSpace
snippet: 

Nicholas Kartsonis, head of clinical research in infectious diseases and vaccines at Merck Research Laboratories, noted that additional treatment options are needed for critically ill patients with respiratory infections.